Inhibikase Therapeutics’ $45 Million Follow-On Public Offering

Martina Bellini
Tagged:

Troutman Pepper Hamilton Sanders LLP advised Inhibikase Therapeutics, Inc. on the deal.Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

…

This content is for Standard 1 Year members only.
Login Join Now